Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.

Michael MianNorbert PescostaStefania BadialiPaola Cristina CappellettoLuigi MarcheselliStefano LuminariFrancesca PatriarcaRenato ZambelloAnna PascarellaGiuseppe TagarielloAlessandra MarabesePatrizia MondelloAtto BillioSergio Cortelazzo

Published in: British journal of haematology (2018)

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
acute myeloid leukemia
low dose
peritoneal dialysis
acute lymphoblastic leukemia
prognostic factors
clinical trial
open label
randomized controlled trial
patient reported outcomes
study protocol